Graticule Asia Macro Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-17,390
Closed -$3.25M 184
2021
Q1
$3.25M Buy
+17,390
New +$3.4M 0.54% 50
2018
Q4
Sell
-8,700
Closed -$934K 160
2018
Q3
$934K Buy
8,700
+5,600
+181% +$560K 0.05% 129
2018
Q2
$265K Buy
3,100
+200
+7% +$16.4K 0.02% 138
2018
Q1
$224K Buy
+2,900
New +$233K 0.02% 136
2017
Q2
Sell
-74,170
Closed -$6.05M 135
2017
Q1
$6.24M Buy
+74,170
New +$5.94M 0.36% 62
2016
Q4
Sell
-125,650
Closed -$10.1M 127
2016
Q3
$10.1M Sell
125,650
-124,500
-50% -$9.97M 0.71% 25
2016
Q2
$19.7M Buy
250,150
+226,621
+963% +$17.1M 2.05% 11
2016
Q1
$1.69M Sell
23,529
-276
-1% -$20.9K 0.13% 65
2015
Q4
$2M Sell
23,805
-220,795
-90% -$18.3M 0.33% 51
2015
Q3
$20.5M Buy
+244,600
New +$20.6M 2.39% 8

Other funds holding LLY

Graticule Asia Macro Advisors's LLY Position: Q2 2021 in Review

Graticule Asia Macro Advisors sold out of Eli Lilly (LLY) in Q2 2021, closing a stake of 17,390 shares — an estimated $3.25M sold.

Graticule Asia Macro Advisors first reported a position in LLY in Q3 2015 and held it in 10 quarters. The position peaked at $20.5M in Q3 2015. 2,022 funds tracked by Wall St. Rank hold LLY as of Q2 2021.

  • Graticule Asia Macro Advisors reported no remaining Eli Lilly position as of Q2 2021 after selling out during the quarter.
  • Graticule Asia Macro Advisors sold 17,390 Eli Lilly shares in Q2 2021, an estimated $3.25M.
  • Graticule Asia Macro Advisors first reported a position in Eli Lilly in Q3 2015 and held it in 10 quarters.
  • Graticule Asia Macro Advisors's Eli Lilly position peaked at $20.5M in Q3 2015.
  • 2,022 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2021.

Based on Graticule Asia Macro Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.